Table of Contents
Definition of Polycystic Ovary Syndrome
Polycystic ovary syndrome is an endocrinological disorder that is characterized by hyperandrogenism, ovarian dysfunction and the identification of multiple cysts in the ovaries. The condition is also associated with metabolic syndrome, hyperinsulinemia and insulin resistance.
Epidemiology of Polycystic Ovary Syndrome
Several diagnostic criteria exist for the diagnosis of polycystic ovary syndrome, some of them are stricter than the others and accordingly, the prevalence of polycystic ovary syndrome is expected to differ according to which diagnostic criteria are used.
Regardless of that, the prevalence of polycystic ovary syndrome is estimated to be 8% to 17% of women in their reproductive age. This figure makes polycystic ovary syndrome one of the most common endocrinological disorders in the population.
Family history of polycystic ovary syndrome, weight gain, sedentary life style, and history of epilepsy disorder all increase the risk of developing polycystic ovary syndrome. Past medical history of valproate use increases the risk of polycystic ovary syndrome. Diabetes is also associated with an increased risk of polycystic ovary syndrome.
Pathophysiology of Polycystic Ovary Syndrome
Patients with polycystic ovary syndrome are usually hyperinsulinemic and they have insulin resistance. It is believed that hyperinsulinemia results in a viscous cycle by facilitating weight gain, increasing free fatty acids in the blood, and worsening insulin resistance. This viscous cycle puts the patient at an increased risk of metabolic syndrome, a common encounter in patients with polycystic ovary syndrome.
Patients with polycystic ovary syndrome develop insulin resistance by increasing the phosphorylation of the insulin receptor. Despite this, hyperinsulinemia alone is not known to affect ovarian theca cells and will not cause a direct increase in androgens production. Hyperinsulinemia when combined with an elevated luteinizing hormone, another pathologic change in polycystic ovary syndrome, induces ovarian theca cells to produce more androgens.
Dyslipidemia occurs in patients with polycystic ovary syndrome due to insulin resistance and excessive hepatic production of triglycerides.
Clinical Presentation of Polycystic Ovary Syndrome
Patients with polycystic ovary syndrome present with hyperandrogenism-related symptoms such as hirsutism, changes in the voice, infertility, and obesity. The menstrual cycle is either irregular or the patient can have amenorrhea.
In addition to this picture, patients with polycystic ovary syndrome also show signs of insulin resistance which are weight gain, glucose intolerance, hyperlipidemia, increased blood pressure and acanthosis nigricans.
Diagnostic Work-up for Polycystic Ovary Syndrome
Late-onset congenital adrenal hyperplasia can have a similar presentation to polycystic ovary syndrome and should be excluded. Serum 17-hydroxyprogesterone levels are elevated after cosyntropin challenge in patients with this disease but not in polycystic ovary syndrome.
24-hour urine collection for cortisol can be used to exclude Cushing syndrome. Patients with no signs of acromegaly do not need further work-up to exclude the diagnosis. If the patient has a picture that is similar to acromegaly, serum insulin-like growth factor 1 can be checked which is not elevated in polycystic ovary syndrome.
Once the exclusion of the other diseases known to cause hyperandrogenism is finished, the first criterion for the diagnosis of polycystic ovary syndrome is met.
The next step is to confirm hyperandrogenism biochemically. Free to total testosterone is very specific and is usually elevated in patients with polycystic ovary syndrome. Additionally, patients with polycystic ovary syndrome have a low level of sex hormone-binding globulin. Dehydroepiandrosterone sulfate is elevated in hyperandrogenism from adrenal origin but not in polycystic ovary syndrome.
As we explained in the pathophysiology section, hyperinsulinemia alone is unlikely to cause hyperandrogenism in these patients. Luteinizing hormone (LH) is also elevated in polycystic ovary syndrome but follicle-stimulating hormone (FSH) is normal. This gives an LH/FSH ratio that is usually above 3 in polycystic ovary syndrome.
Glucose tolerance test is indicated in the evaluation of these patients to exclude glucose intolerance, a common complication of the disorder. Additionally, women with polycystic ovary syndrome who become pregnant are at risk of developing gestational diabetes and they should be closely monitored. Dyslipidemia can complicate the picture and the patient might have a total cholesterol level that is above 200 mg/dl or an LDL-cholesterol level above 160 mg/dl.
After the exclusion of the other causes of hyperandrogenism and the confirmation of biochemical and clinical hyperandrogenism, ovarian dysfunction has to be confirmed as well. Ovarian dysfunction in polycystic ovary syndrome can be identified from the clinical history: amenorrhea or irregular menstrual cycle, or from the abnormal LH/FSH ratio. The final criterion in the diagnosis of polycystic ovary syndrome is to visualize polycystic ovaries on imaging or laparoscopy.
Transvaginal ultrasonography is preferred for the visualization of pelvic organs including the ovaries. This helps confirm the diagnosis by visualizing multiple ovarian cysts and also excluding other causes of menstrual dysfunction such as endometriosis or anatomical uterine abnormalities.
If the risk of ovarian malignant cyst is high, abdominal CT scan or MRI is indicated to further study the cyst and exclude tumor extension.
If more than 12 cysts can be identified in one ovary, the diagnosis of polycystic ovaries is made. This is different from polycystic ovary syndrome in which the number of the ovarian cysts need not to be 12.
Treatment of Polycystic Ovary Syndrome
Treatment of polycystic ovary syndrome includes treatment that is against the hyperandrogenism state, treatment of menstrual abnormalities, and treatment of infertility when pregnancy is wanted. Other symptomatic treatment of hyperinsulinemia and metabolic syndrome is also indicated.
Premenopausal women with polycystic ovary syndrome who present with hirsutism benefit from oral contraceptive pills. Additionally, laser and mechanical hair removal is usually required for better results. After six months, if the patient still complains from hirsutism, then antiandrogens can be used.
Dienogest is a new progestin that has antiandrogenic activity and can be used in patients not responding to typical combined oral contraceptive pills. Spironolactone is another possible treatment for hyperandrogenism.
As we have explained, hyperinsulinemia plays a role in the hyperandrogenic state in polycystic ovary syndrome by a co-androgenic effect with luteinizing hormone. Accordingly, metformin and thiazolidinediones have been used with success in the treatment of hirsutism and hyperandrogenism in this condition. These drugs work by increasing insulin sensitivity and they are also expected to help the patient lose weight, improve their lipid profile, and improve glucose intolerance.
Patients with polycystic ovary syndrome also have menstrual abnormalities that need to be fixed. Combined oral contraceptive pills help by fixing the cycle irregularity. Additionally, weight loss improves the semiology of these patients by decreasing insulin resistance and can also help with the menstrual abnormalities.
Polycystic ovary syndrome can be identified as the etiology of infertility in some women and these women need treatment to help with getting pregnant. The first-line therapy to improve fertility in polycystic ovary syndrome is to lose weight.
Clomiphene citrate is used in women with polycystic ovary syndrome who are infertile. Clomiphene is an antiestrogenic that acts on the hypothalamus and leads to an increase in the pulse frequency of gonadotropin releasing hormone (GnRH) which manifests as an elevation in FSH concentration. This fixes the LH/FSH ratio which is known to be impaired in polycystic ovary syndrome which results in more ovulatory cycles and the probability of having an ovulatory cycle is estimated to be about 85% after starting treatment.
As the main cause of infertility in polycystic ovary syndrome is related to anovulation, restoring ovulation achieve pregnancy in up to 60% of the women in the first six months of treatment.
Metformin can also be used in women with infertility due to polycystic ovary syndrome as it was shown to induce ovulation before.
Women who do not achieve ovulation by medical treatment are candidates for laparoscopic ovarian drilling (LOD) or gonadotropins. FSH administration, a gonadotropin, can achieve pregnancy but has several side effects such as ovarian hyperstimulation syndrome. LOD is recommended when the patient does not want gonadotropin therapy or when surgery is indicated for other reasons.
Laser or electrocautery is used to drill up to ten holes in the ovary stroma. Fortunately, in women who did not respond to clomiphene, a single trial with LOD can achieve ovulation in up to 92% and pregnancy in 58%. The morbidly obese and patients with severe hyperandrogenism are less likely to achieve pregnancy with LOD if they are resistant to clomiphene.
Women who do not achieve pregnancy with the above methods are candidates for in-vitro fertilization. Fortunately, the risk of miscarriage or other complications in women with polycystic ovary syndrome who undergo in-vitro fertilization is similar to the general population of in-vitro fertilization patients.